Nose-to-brain delivery has a rat problem

Nick Taylor at filed an interesting report on nose-to-brain drug delivery from the American Association of Pharmaceutical Scientists' annual meeting in New Orleans. The nose remains a promising route to the central nervous system, but the problem is that, so far, most of the testing has been done on rats, which have very different noses than humans. Taylor mentions OptiNose, which we profiled in September, and its breath-activated device. Studies suggest the device is capable of nose-to-brain delivery, said Per Djupesland, the company's chief scientific officer. Unfortunately, the rat-human problem is there again, so validation is difficult. With a rat, you can sacrifice it to view the brain. This is frowned upon in human trials. Report

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.